Determining clinically meaningful thresholds for innovative burn care products to reduce autograft: A US burn surgeon Delphi panel

Construction of an instrument to evaluate the quality of hospital care provided in burns units in Brazil: A Delphi study

BACKGROUND

Providing excellent care to patients with acute burns can result in lower mortality and disability in the long-term. There are no specific instruments to evaluate the quality of care provided at this stage of treatment. This study aims to create an instrument to evaluate the quality of hospital care provided to patients with acute burns in Brazil.

METHODS

The Delphi technique was used to obtain a consensus among experts on which constructs should be incorporated into the instrument. The sample comprised professionals experienced in treating burn victims and subscribed to the Brazilian Society of Burns mailing lists. Each statement was judged on a 5-point Likert scale. A percentage of agreement equal to or higher than 75 % was defined as a consensus. Data were analyzed using content analysis and descriptive summary statistics.

RESULTS

The first round obtained responses from 34 experts, with a mean of 11.98 (SD 9.29) years of experience. After three rounds, 106 statements reached consensus for inclusion and served as the basis for the instrument.

CONCLUSION

Our study identified key terms, and consensus was reached on 106 statements; a need to define clear outcome evaluation methods was observed.

A phase 3b, open-label, single-arm, multicenter, expanded-access study of the safety and clinical outcomes of StrataGraft® treatment in adults with deep partial-thickness thermal burns

BACKGROUND

A phase 3b, open-label, multicenter, expanded-access study (NCT04123548) evaluated safety and clinical outcomes of StrataGraft treatment in adults with deep partial-thickness thermal burns with intact dermal elements.

METHODS

Adult patients with 3 % to < 50 % total body surface area burns were treated with a single application of ≤ 1:1 meshed StrataGraft and followed for 24 weeks. Primary endpoint was count and percentage of patients with treatment-emergent adverse events (TEAEs). Secondary endpoints included confirmed wound closure (WC) at Week 12, durable WC at Week 24, time to WC, scar evaluation, and wound infection-related events.

RESULTS

Fifty-two patients with 96 treatment sites were enrolled. Pruritus was the most common TEAE (22 patients [42.3 %]). Twenty serious TEAEs occurred in 10 patients (19.2 %); none were related to StrataGraft. There were 4 (7.7 %) deaths (aspiration, myocardial infarction, self-injury, Gram-negative rod sepsis); none were related to StrataGraft. Confirmed WC was achieved by Week 12 in 33 patients (63.5 %; 95 % CI: 50.4-76.5 %) and 69 treatment sites (71.9 %; 95 % CI: 62.9-80.9 %). Durable WC was achieved by Week 24 in 29 patients (55.8 %; 95 % CI: 42.3-69.3 %) and 58 treatment sites (60.4 %; 95 % CI: 50.6-70.2 %).

CONCLUSIONS

StrataGraft demonstrated clinical benefit. Safety data were consistent with previously reported findings.